Bookmark

Add to MyYahoo RSS

Eisai Co News

News on Eisai Co (Ticker: ESALY) continually updated from thousands of sources around the net.

Tuesday Apr 15 | Sys-Con Media

Eisai CEO Haruo Naito Appointed Knight Commander of British Empire

Tokyo, Apr 15, 2014 - - Eisai Co., Ltd. announced today that in recognition of his valuable contribution to relations between Britain and Japan, Her Majesty Queen Elizabeth II has appointed Dr. Haruo Naito, President & CEO of Eisai Co., Ltd. to be an Honorary Knight Commander of the Order of the British Empire .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Europe, World News, United Kingdom

Mon Apr 14, 2014

Customer Interaction Solutions

Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director

Receptos, Inc. , a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the appointment of Mary Lynne Hedley, Ph.D. as a director of Receptos.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, MGI PHARMA, Texas

Fri Apr 11, 2014

PR-inside.com

Global amyotrophic lateral sclerosis drugs market forecast to expand by 5.4% CAGR during 2013 to 2018

One of the key factors contributing to this market growth is the increasing global aging population.

Comment?

Related Topix: Als, Health, Rilutek, Riluzole (generic), Biotech, Healthcare Industry, GlaxoSmithKline

Mon Apr 07, 2014

Sys-Con Media

Eisai Launches New Energy Drink 'Joma'

"Cast a Spell of Happiness" Tokyo, Apr 7, 2014 - - Eisai Co., Ltd. announced that it launched its new energy drink, Joma, in Japan today, April 7. With the slogan "Cast a spell of happiness", Joma is an energy drink designed to conjure up the image ofa witch, whose powers transcend human abilities.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Vitamin B6, Supplement

Mon Mar 31, 2014

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

ETS2101 well tolerated with no serious adverse events. Early evidence of possible hal...

Comment?

Related Topix: Biotech, Medicine, Eisai, Healthcare Industry, AB Electrolux, Appliances

Sys-Con Media

Eisai Assigns Its Worldwide Exclusive License for DACOGENA to Otsuka

We give our first thoughts to patients and their families, and helping to increase the benefits health care provides.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eisai, Marketing

Business Wire

Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen from Eisai

Otsuka has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen A .

Comment?

Related Topix: Biotech, Medicine, Eisai, Healthcare Industry, Startups, SuperGen, Marketing

Tue Mar 25, 2014

Sys-Con Media

Notice Concerning Voluntary Adoption of International Financial Reporting Standards

Tokyo, Mar 25, 2014 - - Eisai Co., Ltd. announced today that, at a meeting of its Board of Directors held earlier today, it resolved to voluntarily adopt International Financial Reporting Standards for consolidated financial statements in lieu of the Japanese Generally Accepted Accounting Principles it has currently adopted.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Mar 21, 2014

Pharmaceutical Online

Eisai Partners With Liverpool Institutions To Develop Drugs

Eisai Co., Ltd. announced it has entered into collaboration with two Liverpool educational institutions to identify and develop drugs for anti-wolbachia therapy against filariasis.

Comment?

Related Topix: Biotech, Healthcare Industry, Lancashire County, England, Europe, World News, United Kingdom, Merseyside County, England, Cheshire County, England

Wed Mar 19, 2014

Sys-Con Media

Eisai Enters Collaboration with Liverpool School of Tropical Medicine ...

Joint Research Project Awarded Ghit Fund Grant Tokyo, Mar 20, 2014 - - Eisai Co., Ltd. announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine and University of Liverpool to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis , both major types of filariasis.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Lancashire County, England, Europe, World News, United Kingdom, Merseyside County, England, Cheshire County, England, Non-Profit, Infectious Diseases

•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••
•••